⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367790 | 0.80 | NOTUM (0.33) | — | |
| SCHEMBL17144788 | 0.78 | CA1 (0.35) | — | |
| SCHEMBL232211 | 0.72 | — | — | |
| SCHEMBL3991 | 0.72 | — | — | |
| SCHEMBL17144664 | 0.71 | GABRG2 (0.38) | — | |
| SCHEMBL7648163 | 0.70 | — | — | |
| SCHEMBL9561983 | 0.70 | — | — | |
| SCHEMBL7644924 | 0.70 | — | — | |
| SCHEMBL9450629 | 0.70 | — | — | |
| SCHEMBL455976 | 0.70 | CA12 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242945-B2 | Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2016-01-26 | — | — | US | claimed |
| US-20140086941-A1 | SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-03-27 | — | — | US | claimed |
| WO-2012166586-A1 | SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-12-06 | — | — | WO | claimed |
| EP-2903990-B1 | THERAPEUTICALLY ACTIVE OXAZOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2017-06-14 | — | — | EP | disclosed |
| US-9382263-B2 | Therapeutically active oxazoline derivatives | UCB BIOPHARMA SPRL (BE) | 2016-07-05 | — | — | US | disclosed |
| US-9242945-B2 | Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150274748-A1 | Therapeutically Active Oxazoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2015-10-01 | — | — | US | disclosed |
| EP-2903990-A1 | THERAPEUTICALLY ACTIVE OXAZOLINE DERIVATIVES | UCB Biopharma SPRL (BE) | 2015-08-12 | — | — | EP | disclosed |
| CN-104147011-A | Uses of pyridine-diketone serving as PDE4 inhibitor for treating eye diseases | ASTRAZENECA AB | 2014-11-19 | — | — | CN | disclosed |
| US-20140275065-A1 | SUBSTITUTED 7-AZABICYLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014053581-A1 | THERAPEUTICALLY ACTIVE OXAZOLINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2014-04-10 | — | — | WO | disclosed |
| US-6777428-B1 | INHIBIT PEPTIDE EXTRAVASATION DUE TO STIMULATION OF THE TRIGEMINAL GANGLIA, AND ARE THEREFORE USEFUL FOR THE TREATMENT OF MIGRAINE AND ASSOCIATED DISORDERS | ELI LILLY AND COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-6653330-B2 | Such as 4'-chloro-4-(5-(3-(2,4-difluorophenyl)-3-hydroxy-2-methyl-4-(1H-1,2,4 -triazol-1-y)butyl)-1,3-dioxan-2-yl)-benzanilide; antifungal activity | SANKYO COMPANY, LIMITED (JP) | 2003-11-25 | — | — | US | disclosed |
| US-20030176480-A1 | For therapy and prophylaxis of fungal infections | SANKYO COMPANY, LIMITED (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1284267-A1 | TRIAZOLE COMPOUNDS HAVING AMIDE LINKAGE | Sankyo Company, Limited (JP) | 2003-02-19 | — | — | EP | disclosed |
| EP-0752873-A4 | LABELLED PEPTIDE COMPOUNDS | MALLINCKRODT INC (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1153013-A2 | 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000047559-A2 | 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2000-08-17 | — | — | WO | disclosed |
| EP-0752873-A1 | LABELLED PEPTIDE COMPOUNDS | MALLINCKRODT MEDICAL, INC. (US) | 1997-01-15 | — | — | EP | disclosed |
| WO-1995022341-A1 | LABELLED PEPTIDE COMPOUNDS | MALLINCKRODT MEDICAL, INC. (US) | 1995-08-24 | — | — | WO | disclosed |